Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection...

Full description

Bibliographic Details
Main Authors: Simona De Gregori, Eleonora Gelli, Mara Capone, Giulia Gambini, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Gianluca Martini, Ludovica Calabretta, Luca Arcaini, Riccardo Albertini, Patrizia Zappasodi
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Pharmaceutics
Subjects:
acute myeloid leukemia
elderly patients
venetoclax
posaconazole
HPLC-MS/MS
dose adjustment
Online Access:https://www.mdpi.com/1999-4923/15/6/1680

Internet

https://www.mdpi.com/1999-4923/15/6/1680

Similar Items